^
    1d
    Plasma Calcitonin Gene-Related Peptide (CGRP) Levels in Patients With Head and Neck Malignancies Undergoing Radiotherapy (clinicaltrials.gov)
    P=N/A, N=23, Completed, West China Hospital | Recruiting --> Completed | N=50 --> 23 | Trial completion date: Dec 2026 --> Apr 2026 | Trial primary completion date: Aug 2026 --> Apr 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    1d
    Medical Data Collection of Patients With Head and Neck Cancer Treated With Proton Therapy (clinicaltrials.gov)
    P=N/A, N=450, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Apr 2026 --> Apr 2032 | Trial primary completion date: Apr 2026 --> Apr 2032
    Trial completion date • Trial primary completion date
    1d
    Phase II Randomized-registry Embedded Study of Lymphoscintigraphy for Oropharyngeal Neoplasms to Enable Risk-adapted Nodal Guidance for Robotic Surgery and/or Radiotherapy (LONE-RANGR2) (clinicaltrials.gov)
    P2, N=8, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=240 --> 8
    Enrollment closed • Enrollment change
    1d
    Supportive Oncology Care At Home RCT (clinicaltrials.gov)
    P=N/A, N=300, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    2d
    AdMSC spheroids encapsulating antioxidant hybrid protein carrier for irradiation-damaged salivary gland repair. (PubMed, Bioact Mater)
    These results demonstrate the synergistic effects of ROS-scavenging activity from GC and paracrine signaling from AdMSC spheroids. This groundbreaking spheroid-encapsulating GC improves SG regeneration and functional recovery by integrating antioxidant activity with angiogenic effects, offering a paradigm-shifting solution for other oxidative stress-mediated tissue disorders.
    Journal
    |
    NOX4 (NADPH Oxidase 4) • SOD2 (Superoxide Dismutase 2)
    2d
    Significance of SLC1A5 expression in head and neck squamous cell carcinoma: A bioinformatics and in-vitro analysis. (PubMed, J Oral Biol Craniofac Res)
    While STRING analysis does not confer great significance to prognosis, it accentuates SLC1A5 as a hub in amino acid metabolism and tumor progression pathways in HNSC. The overexpression of SLC1A5 is linked with unfavorable survival in HNSCC, highlighting its value to the metabolic reprogramming in HNSCC.
    Preclinical • Journal
    |
    SLC1A5 (Solute Carrier Family 1 Member 5)
    2d
    Cytotoxicity of Green Synthesized Silver Nanoparticles Against Oral Cell Lines: A Systematic Review and Meta-Analysis. (PubMed, J Biochem Mol Toxicol)
    The GS-AgNPs also exhibited selective cytotoxicity towards oral cancer cell lines, influenced by nanoparticle size, shape, and concentration. Their favorable biocompatibility and selective anticancer activity support their potential application in oral cancer therapy.
    Clinical • Preclinical • Retrospective data • Review • Journal
    |
    ANXA5 (Annexin A5)
    2d
    Vebectotamab Vedotin Combined With Pucotelimab in the Treatment of Locally Advanced Laryngeal Carcinoma (clinicaltrials.gov)
    P1/2, N=10, Not yet recruiting, Tang-Du Hospital
    New P1/2 trial
    |
    vibecotamab (XmAb14045)
    3d
    RCT of GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC. (clinicaltrials.gov)
    P3, N=442, Not yet recruiting, Sun Yat-sen University
    New P3 trial
    |
    cisplatin • gemcitabine • Focus V (anlotinib) • Loqtorzi (toripalimab-tpzi)
    3d
    GZMK expression within activated intratumoral T-cell subsets reflects differentiation efficiency and predicts response to cancer immunotherapy. (PubMed, NPJ Precis Oncol)
    Together, our findings demonstrate that GZMK+ T cell profiles reflect baseline anti-tumor immunocompetence and offer a clinically actionable biomarker for predicting immunotherapy response. NCT04247282, ClinicalTrails.gov, registered 1/30/2020 and NCT03429036, ClinicalTrails.gov, registered 11/06/2020.
    Journal • IO biomarker
    |
    GZMK (Granzyme K)
    4d
    Understanding Tumor Microenvironment Dynamics and Immune Checkpoint Inhibitor Efficacy Following mEGFR-Targeted Near-Infrared Photoimmunotherapy. (PubMed, Cancer Lett)
    This preclinical NIR-PIT model would provide valuable insights into improving treatment strategies. (250 words).
    Journal • Checkpoint inhibition • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    EGFR expression
    4d
    Interleukin-8: a tumor-agnostic biomarker integrating cancer biology and host response across solid tumors. (PubMed, Cancer Treat Rev)
    In particular, IL-8 has emerged as a promising prognostic and predictive biomarker of resistance to immune checkpoint inhibitors. This review highlights its prognostic and predictive value across gastrointestinal, genitourinary, lung, melanoma, breast, ovarian, and head and neck cancers, and discusses strategies targeting IL-8 and the need for standardized, clinically actionable assays.
    Review • Journal • IO biomarker • Pan tumor
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCR1 (Chemokine (C-X-C motif) receptor 1)